These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
466 related articles for article (PubMed ID: 24265793)
1. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. Birkbak NJ; Kochupurakkal B; Izarzugaza JM; Eklund AC; Li Y; Liu J; Szallasi Z; Matulonis UA; Richardson AL; Iglehart JD; Wang ZC PLoS One; 2013; 8(11):e80023. PubMed ID: 24265793 [TBL] [Abstract][Full Text] [Related]
2. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299 [TBL] [Abstract][Full Text] [Related]
3. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259 [TBL] [Abstract][Full Text] [Related]
4. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer. Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392 [TBL] [Abstract][Full Text] [Related]
6. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. George J; Alsop K; Etemadmoghadam D; Hondow H; Mikeska T; Dobrovic A; deFazio A; ; Smyth GK; Levine DA; Mitchell G; Bowtell DD Clin Cancer Res; 2013 Jul; 19(13):3474-84. PubMed ID: 23633455 [TBL] [Abstract][Full Text] [Related]
7. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. Alsop K; Fereday S; Meldrum C; deFazio A; Emmanuel C; George J; Dobrovic A; Birrer MJ; Webb PM; Stewart C; Friedlander M; Fox S; Bowtell D; Mitchell G J Clin Oncol; 2012 Jul; 30(21):2654-63. PubMed ID: 22711857 [TBL] [Abstract][Full Text] [Related]
8. Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers. Labidi-Galy SI; de La Motte Rouge T; Derbel O; Wolfer A; Kalbacher E; Olivier T; Combes JD; Heimgartner-Hu K; Tredan O; Guevara H; Heudel PE; Reverdy T; Bazan F; Heinzelmann-Schwarz V; Fehr M; de Castelbajac V; Vaflard P; Crivelli L; Bonadona V; Viassolo V; Buisson A; Golmard L; Rodrigues M; Ray-Coquard I Gynecol Oncol; 2019 Nov; 155(2):262-269. PubMed ID: 31604666 [TBL] [Abstract][Full Text] [Related]
9. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894 [TBL] [Abstract][Full Text] [Related]
10. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. Hennessy BT; Timms KM; Carey MS; Gutin A; Meyer LA; Flake DD; Abkevich V; Potter J; Pruss D; Glenn P; Li Y; Li J; Gonzalez-Angulo AM; McCune KS; Markman M; Broaddus RR; Lanchbury JS; Lu KH; Mills GB J Clin Oncol; 2010 Aug; 28(22):3570-6. PubMed ID: 20606085 [TBL] [Abstract][Full Text] [Related]
11. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer. Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357 [TBL] [Abstract][Full Text] [Related]
12. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976 [TBL] [Abstract][Full Text] [Related]
13. Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer. Lee YJ; Kim HS; Rim JH; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT BMC Cancer; 2020 Mar; 20(1):185. PubMed ID: 32131779 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. Boyd J; Sonoda Y; Federici MG; Bogomolniy F; Rhei E; Maresco DL; Saigo PE; Almadrones LA; Barakat RR; Brown CL; Chi DS; Curtin JP; Poynor EA; Hoskins WJ JAMA; 2000 May; 283(17):2260-5. PubMed ID: 10807385 [TBL] [Abstract][Full Text] [Related]
15. Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. Dougherty BA; Lai Z; Hodgson DR; Orr MCM; Hawryluk M; Sun J; Yelensky R; Spencer SK; Robertson JD; Ho TW; Fielding A; Ledermann JA; Barrett JC Oncotarget; 2017 Jul; 8(27):43653-43661. PubMed ID: 28525389 [TBL] [Abstract][Full Text] [Related]
16. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. McLaughlin JR; Rosen B; Moody J; Pal T; Fan I; Shaw PA; Risch HA; Sellers TA; Sun P; Narod SA J Natl Cancer Inst; 2013 Jan; 105(2):141-8. PubMed ID: 23257159 [TBL] [Abstract][Full Text] [Related]
19. Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures. Ow GS; Ivshina AV; Fuentes G; Kuznetsov VA Cell Cycle; 2014; 13(14):2262-80. PubMed ID: 24879340 [TBL] [Abstract][Full Text] [Related]
20. Comparison of Clinical Outcomes of Eoh KJ; Park HS; Park JS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ Cancer Res Treat; 2017 Apr; 49(2):408-415. PubMed ID: 27488874 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]